ArticleAnnals of surgical oncology2023
Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment.
Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Diagnostic lncRNA high expression for liver patients prognosis and medication guidance: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Disappearing Colorectal Liver Metastases: Should the Treatment Sequence Be Reconsidered for Selected Lesions?Cancers · 2026Article
- Association between serum carbohydrate antigen 199 levels and diabetic kidney disease in patients with type 2 diabetes: a retrospective cross-sectional study from Northwest China.BMC endocrine disorders · 2026Article
- Prognostic Role of CA19-9 in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.Cancers · 2026Review
- Impact of sequential perioperative chemotherapy for high-risk colorectal liver metastases.Surgery today · 2026Article
- Predictive value analysis of CEA, CA125 and CYFRA21-1 levels in evaluating the efficacy of tislelizumab combined with gemcitabine-cisplatin chemotherapy in patients with advanced non-small cell lung cancer.Oncology letters · 2026Article
- Construction of a novel prediction model based on albumin-hemoglobin score and serum microRNA-497-5p for prognosis of patients with stage II-III colorectal cancer.Oncology letters · 2026Article
- Preoperative prognostic model combining tumor burden score and tumor markers to predict long-term outcomes following hepatectomy for intrahepatic cholangiocarcinoma: a multi-institutional analysis.Frontiers in oncology · 2026Article
- Significance and Correlation Analysis of Folate Receptor-Positive Circulating Tumor Cells (FR + CTC) in Colorectal Cancer Patients.Cancer reports (Hoboken, N.J.) · 2026Article
- SIRI as a Prognostic Marker in Metastatic Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Prognostic significance of carbohydrate antigen 19-9 (CA19-9) change during immediate postoperative periods in patients with stage I-III colorectal cancer.Annals of coloproctology · 2025Article
- High-Performance Silicon Nanowire Array Biosensor for Combined Detection of Colorectal Cancer Biomarkers.Micromachines · 2025Article
- Prognostic Value of Perioperative Serum Creatinine Kinase Levels for Metachronous Colorectal Liver Metastasis.Cureus · 2025Article
- Dynamic Prognostic Models for Colorectal Cancer With Liver Metastases.JAMA network open · 2025Article
- Association between serum tumor markers and diabetic nephropathy in type 2 diabetes patients: a cross-sectional survey in Western China.BMC endocrine disorders · 2025Article
- Strategies for Recurrent Colorectal Liver Metastases Based on Prognostic Factors and Resectability: Potential Benefit of Multidisciplinary Treatment.Annals of surgical oncology · 2025Article
- Metabolic parameters in F-fluorodeoxyglucose positron emission tomography/computed tomography for treatment response in colorectal carcinoma.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Comprehensive data of 5085 patients newly diagnosed with colorectal liver metastasis between 2013 and 2017: Fourth report of a nationwide survey in Japan.Journal of hepato-biliary-pancreatic sciences · 2025Article
- Patterns and Predictors of Recurrence After Curative Resection of Colorectal Liver Metastasis (CRLM).Journal of gastrointestinal cancer · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough patients with resectable colorectal liver metastasis (CLM), a population with good prognosis, have been treated with upfront surgery, some patients have had a poor prognosis. This study aimed to investigate biologic prognostic factors in patients with resectable CLMs.
methodsThis single-center retrospective study enrolled consecutive patients who underwent liver resection for initial CLMs at the Cancer Institute Hospital between 2010 and 2020. The study defined CLMs as resectable (tumor size < 5 cm; < 4 tumors; no extrahepatic metastasis) or borderline resectable (BR). Preoperative chemotherapy was administered to patients with BR CLMs.
resultsDuring the study period, 309 CLMs were classified as resectable without preoperative chemotherapy and 345 as BR with preoperative chemotherapy. For the 309 patients with resectable CLMs, the independent poor prognostic factors associated with overall survival in the multivariable analysis were high tumor marker levels (CEA ≥ 25 ng/mL and/or CA19-9 ≥ 50 U/mL; (hazard ratio [HR], 2.45; p = 0.0007), no adjuvant chemotherapy (HR, 1.69; p = 0.043), and age of 75 years or older (HR, 2.09; p = 0.012). The 5-year survival rates for the patients with high tumor marker (TM) levels (CEA ≥25 ng/mL and/or CA19-9 ≥50 U/mL) were significantly worse than for those with low TM levels (CEA < 25 ng/mL and CA19-9 < 50 U/mL) (55.3% vs. 81.1%; p <0.0001) and similar to the rate for those with BR CLMs (52.1%; p = 0.864). Postoperative adjuvant chemotherapy had an impact on prognosis only in the high-TM group (HR, 2.65; p = 0.007).
conclusionsHigh TM levels have a prognostic impact on patients with resectable CLMs stratified by tumor number and size. Perioperative chemotherapy improves long-term outcomes for patients with CLM and high TM levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.